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Abstract
Pharmaceutical targeting is one of key inputs for making sales and marketing
strategy planning. Targeting list is built on predicting physician’s sales potential
of certain type of patient. In this paper, we present a time-sensitive targeting
framework leveraging time series model to predict patient’s disease and treatment
progression. We create time features by extracting service history within a certain
period, and record whether the event happens in a look-forward period. Such
feature-label pairs are examined across all time periods and all patients to train a
model. It keeps the inherent order of services and evaluates features associated to
the imminent future, which contribute to improved accuracy.
1 Introduction
A primary goal of oncology pharmaceutical market research is to develop quantitative models for
patients that can be used to predict disease progression, e.g., treatment changes of a patient. In most
physician alert systems for sales and marketing, the selection of physicians to be included in the alert
report is mainly based on their patient’s treatment status. To accurately and quickly identify patient
before the treatment decisions even being made would empower foresight ability and competitive
edge for marketers, allowing the marketers to focus on the right physicians with the right patients at
the right time, before the treatment decisions are made [1, 2].
Traditionally, physician targeting is achieved by training a regression model to predict a doctor’s
number of patients that have been diagnosed by certain disease, or the total volume of certain drug
this doctor prescribed in a given time window [3, 4]. Most physician targeting models are trained
and applied on doctor level, namely, each sample in the model represents a doctor. For enhancing
the targeting accuracy, in this research we propose a time sensitive model to predict doctor’s sales
potential by forecasting patient’s disease progression. Compared with traditional targeting method,
by using electronic health records (EHRs) data, the proposed model is built on patient level to predict
if a patient will have treatment change in the next given time window. For example, predicting if
a cancer patient will start first-line treatment in next three months. Then a doctor’s sales potential
could be accurately estimated as the number the patients who will start first-line treatment in next
three months. Once the messages are deployed, pharma companies may further leverage this data to
demonstrate uptake of a treatment or health outcomes as a way to demonstrate effectiveness of the
program through return of investment design.
Recently, machine learning for clinical prediction is growing more popular, and several recent meth-
ods have been proposed in predicting disease progression. In [5], a deep neural network is trained
using EHR data to extract patients’ latent features that could be used to predict future disease. To
address the non-linear temporality in EHR data, a recurrent neural network based model was proposed
in [6] to predict initial diagnosis of heart failure, and compared with conventional methods that ignore
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temporality. Machine learning algorithms have been proposed to predict patient-level disease pro-
gression in areas of Alzheimer’s disease[7], heart disease[8, 9], cancer[10], lung disease[11], kidney
disease[12], and the progression of multiple diseases using the Hawkes process[13]. Particularly,
machine learning with time series analysis have been applied to process clinical data, for accuracy
enhancement[14, 15].A comprehensive exposition of machine learning with EHR data can be found
in [16, 17, 18, 19].
In this work, we propose an algorithm combining time series analysis and machine learning, and test
it on our real world data-set. The algorithm significantly increase the prediction accuracy comparing
with method ignoring time components. Although in this paper we only provide the results of one
disease area, this model has also been applied in practical pharmaceutical problems in Althemer’s
disease, diabetes and obesity patients’ disease progression, and in all of them the deployments are
successful which illustrate the robustness of the proposed method. Specifically, the algorithm works
as follows. Given the service history for a large number of patients, and the date when a particular
event happens to a small group of them, the model aims to predict which patients will receive the
event in the near future, e.g. in the next 3 months. The model does so via a novel time-series-based
modeling. For each time period of a pre-specified length, the model extracts the service history
of a certain patient within the period, and records whether the event happens to the patient in a
look-forward period. Such feature-label pairs are generated across all possible time periods and all
patients. The model is trained on such generated data using machine-learning-based approach. This
model has the advantages of keeping the inherent order of received services, identifying features
related to the near future, as well as features yielding no events, all of which are ignored by other
algorithms. The proposed algorithm improves accuracy in the imminent future event prediction.
In traditional predictive analysis of pharma marketing research, the objective is identify the predefined
event, and trying classify the unknown sample into event and nonevent groups, e.g., [20, 21]. All
sample information are collected through historical static time period, including event status and
sample features. Sample is split into training and testing as two mutually exclusive groups. Model is
built with training sample and applied upon testing sample. The validation is performed also on testing
sample to measure difference between estimation and observation. Normally these measurements
of model accuracy are performed within the same time period. However, when model is applied to
sample collected through future time, the validation of model accuracy becomes conversion rate,
which is out of estimated event sample, how many will be observed in short time period. This accuracy
of model validation through future sample will be significantly reduced in most cases. The time
constraint of when event will happen is not supported by traditional predictive modeling. However,
this is critical for sales field to plan and measure the trigger alert strategy. The newly developed
model is integrating timing component and leveraging forecasting techniques, to re-engineering data
structure, event, and feature, and ultimately improve conversion rate in future time frame. The new
model shows significant improvement compared with traditional predictive model on conversion rate.
2 Method
We extract data from IQVIA database including hundreds of millions longitudinal prescription
(Rx) and medical claims (Dx). In this study, we focus on one particular cancer, an chronic cancer
that there is a watch-and-wait period before patient start first line treatment. IQVIA receives 2
billion prescription claims per year with history from January 2004 with coverage up to 88% for the
retail channel, 50-70% for traditional and specialty mail order, and 40% for long-term care. This
information represents activities during the prescription transaction including product, provider, payer
and geography. In this study, we pulled relevant Rx/Dx data from January 2010 to January 2018.
2.1 Proposed Model Framework
Conventionally, treatment prediction problems have been commonly modeled as a classification
problem. For a patient p, the model seeks to learn the mapping from the features xp to the label yp,
xp = [wp1 , w
p
2 , . . . , w
p
I , z
p
1 , z
p
2 , . . . , z
p
D] 7→ yp. (1)
In the equation, wpi denotes the count of the i-th service experienced by the patient, where the
services may include drugs, other related treatments, examinations, etc., zpi denotes demographical
information of the patient, and yp is the patient label. A machine learning model is then trained upon
the features xp and labels yp across all P patients using data up to today.
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Figure 1: Generating time-dependent claim-level features where each time index represents one day.
For a pre-determined index date t, service records for δ∆ days prior to the index date are aggregated
into ∆ buckets, each with length δ.
0 2000 4000 6000 8000 10000
Potential patients predicted
0
200
400
600
800
1000
Tr
ue
 tr
ea
te
d 
pa
tie
nt
s
single record
multiple records
no time modeling
with time difference
Figure 2: The K-accuracy curve and the number of successfully predicted patients who received the
treatment in the following 12 months.
Despite its widespread usage in the healthcare and pharmaceutical industry, such model has 3 major
problems: (i) The model is trained to predict who will receive the treatment eventually, but the
problem of real interest is who will receive the treatment in the near future. (ii) The services of the
patient in the previous months and the services of the patient in the previous years are treated equally,
since they are all condensed into the counts wi. (iii) The ordering of different services, e.g. service i
before service j, are ignored.
In order to solve these challenges, we introduce a time sensitive model so that the count wi for each
service is separated into the count of services for each day, wi = wi,1 + wi,2 + . . . wi,T across the T
days examined in the data. Also, we could separate the patient label for each day y = y1 +y2 + . . . yT ,
where for patients who received the treatment, i.e. y = 1, there is one time index t such that yt = 1
and yτ = 0 for all other time indexes 1 ≤ τ ≤ T, τ 6= t, and for patients who have not received the
treatment, i.e. y = 0, yτ = 0 for all time indexes 1 ≤ τ ≤ T . The introduction of time tends to make
wi,t very sparse, and is therefore likely to result in unstable models. In order to make the generated
time-based features more robust, we aggregate service records in wi,t across multiple time indexes
t for each the i-th service. In specific, for each service i and a pre-chosen index date t when we
examine the label yt, the total amount of services for the previous δ days is computed and recorded
li,1 =
t−δ∑
ν=t−1
wi,ν . (2)
The δ-day sum is evaluated for ∆ intervals covering δ∆ days prior to the index date, i.e. we compute
li,τ =
t−δτ∑
ν=t−(τ−1)δ−1
wi,ν . (3)
for each interval 1 ≤ τ ≤ ∆. Finally, we train a neural network on the time-dependent features li,τ
across the ∆ intervals and I services. These time-dependent claim-level features are combined with
demographical information to predict the label,
[l1,1, l2,1, . . . , l1,∆, l2,1, l2,2, . . . , l2,∆, . . . , lI,1, lI,2, . . . , lI,∆, z1, z2, . . . zD] 7→ y. (4)
As an illustration, Figure 1 depicts how claim-level features are constructed with total time indexes
T = 8, total services I = 3, interval length δ = 2, and number of intervals ∆ = 2. When t = 5, as
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Table 1: The number of successfully predicted treatments from Nov-11-2016 to Nov-11-2017 among
the K selected patients across the 4 models, and the improvement of the proposed model.
K 1,000 2,000 3,000 5,000 7,000 10,000
Proposed Alg. 123 217 333 537 726 978
Count 79 174 252 445 600 865
Count + TD 69 150 231 433 637 909
Proposed Alg. vs. Count 55.70% 24.71% 32.14% 20.67% 21.00% 13.06%
Proposed Alg. vs. Count + TD 78.26% 44.67% 44.16% 24.02% 13.97% 7.59%
colored in blue, for each service i, we generate a feature wi,1 + wi,2 and another feature wi,3 + wi,4
by aggregating the 4 days prior to t into 2 buckets.
Thereafter, for positive patients with y = 1 who received the treatment, her index date t is set to be
the day when the treatment was received. For negative patients with y = 0 who have not received the
treatment, her index date t is set to be the split date tsplit, i.e. the most recent date in the database.
3 Experiment
The dataset has 139, 816 patients and spans the clinical records from 2013 and 2016. We set the split
date tsplit to be Nov-11-2016, and use only the claim data prior to tsplit to generate features, train
the model, and perform offline validation. For each of the models trained, it is asked to predict K
patients who had not received the treatment prior to or on tsplit and whom the model believes are the
most likely to receive the treatment. We then examine how many of the predicted K patients indeed
received the treatment between Nov-11-2016 and Nov-11-2017, and use the accuracy of prediction as
the performance metric. We note that this experiment is analogy to time-series stock prediction, i.e.
given all stock performance in the four years prior to Nov-11-2016, train models to predict K stocks
which are expected to perform the best in the following year, and then we evaluate how many of these
K stocks are indeed the top performer from Nov-11-2016 to Nov-11-2017. We are evaluating the
models in a pure online way, which is much harder than most existing methods which train a model
and apply the model to predict the remaining patients in the same time interval.
We construct time-sensitive claim-level features using time indexes T = 1, 411, services I = 26,
demographical features D = 28 (including 18 dummy binary variables), interval length δ = 91 (each
time bucket is for one quarter), and number of intervals ∆ = 2, probability for negative prior treatment
to be included q = 0.3. This results in 80 number of features. The demographical information are
constructed using data on the split date. As benchmarks, we consider the conventional model with
features in (1) fed into a deep neural network model (named no time modeling in Figure 2); we also
consider adding features that represent the time difference between the diagnosis date and the date
when the patient received each of the treatments for the first time (named time difference (TD) in
Figure 2). Out of the 123, 260 potential patients who had not received the treatment by Nov-11-2016,
6, 909 of them (5.61%) received the treatment between Nov-11-2016 and Nov-11-2017.
A model is trained using the deep neural network with dropout ratio of 20%. The deep neural
network is better than random forest, xgboost, and regression based models on this expecriment. The
K-accuracy curve and the number of successfully predicted patients who received the treatment in the
following 12 months are presented in Figure 2 and Table 3 respectively. It can be seen that in average,
the proposed methods with time-dependent features improve the accuracy by more than 20% in both
conventional model with no time information and the model with time difference information. From
a business perspective, this indicates that out of 100 sales call, conventional method is expected to
identify 8 to 9 patients who would receive treatments in the near future and make the deal with them,
while the proposed method with time-dependent features is expected to identify 10 to 11 patients,
resulting in 2 to 3 more sales compared to the conventional models.
4 Conclusion
This research is developing a time sensitive predictive modeling to first identify patients with high
potential to change treatment and most importantly, this model will bring an innovative approach to
integrate forecasting technique with predictive modeling to enhance accuracy of the prediction. The
overall lift of accuracy rate in forecasting time period doubled the traditional results in the simulation
process. More research are undergoing to further improve the accuracy of the final results.
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